Chapter 2
Semaglutide as a Single-Agent Strategy for Diabetes, Obesity, and Hypertension: An 18-Month Case Experience
- By Kamolika Chaudhary, Abhishek Anand, Mithul V Mammen, Amit Kumar - 26 Sep 2025
- Zentoks Series in Pharmacy Science, Volume: 1, Pages: 7 - 9
Abstract/Preface
GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity, demonstrating strong efficacy in glycaemic control, weight loss, and cardiovascular protection. Landmark drugs like tirzepatide and semaglutide improve renal outcomes and are being investigated for conditions such as liver disease, arthritis, and neurodegeneration. Increasing evidence highlights their antihypertensive potential. We report an 18-month case study of an obese type 2 diabetic patient with uncontrolled hypertension who achieved significant weight loss, normalized blood pressure, and a sustained reduction in HbA1c (from 9.2% to 6.0%) without antihypertensive or lipid-lowering drugs. Mechanistically, GLP-1 receptor agonists may enhance vascular function through nitric oxide pathways, endothelial modulation, weight reduction, and suppression of the renin-angiotensin-aldosterone system (RAAS). Clinical studies and empirical data underscore GLP-1 receptor agonists as versatile medications that mitigate metabolic, cardiovascular, and renal risks, facilitating their integration into comprehensive treatment plans for high-risk metabolic diseases.